Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens
Field | Value | Language |
dc.contributor.author | Counoupas, Claudio | en_AU |
dc.contributor.author | Pino, Paco | en_AU |
dc.contributor.author | Stella, Alberto O. | en_AU |
dc.contributor.author | Ashley, Caroline | en_AU |
dc.contributor.author | Lukeman, Hannah | en_AU |
dc.contributor.author | Bhattacharyya, Nayan D. | en_AU |
dc.contributor.author | Tada, Takuya | en_AU |
dc.contributor.author | Anchisi, Stephanie | en_AU |
dc.contributor.author | Metayer, Charles | en_AU |
dc.contributor.author | Martinis, Jacopo | en_AU |
dc.contributor.author | Aggarwal, Anupriya | en_AU |
dc.contributor.author | Dcosta, Belinda M. | en_AU |
dc.contributor.author | Kint, Joeri | en_AU |
dc.contributor.author | Wurm, Maria J | en_AU |
dc.contributor.author | Landau, Nathaniel R. | en_AU |
dc.contributor.author | Steain, Megan | en_AU |
dc.contributor.author | Turville, Stuart G | en_AU |
dc.contributor.author | Wurm, Florian M | en_AU |
dc.contributor.author | David, Sunil A. | en_AU |
dc.contributor.author | Triccas, James A. | en_AU |
dc.date.accessioned | 2021-09-16T22:00:44Z | |
dc.date.available | 2021-09-16T22:00:44Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/2123/26142 | |
dc.description.abstract | ABSTRACT Global control of COVID-19 will require the deployment of vaccines capable of inducing long-term protective immunity against SARS-CoV-2 variants. In this report, we describe an adjuvanted subunit candidate vaccine that affords elevated, sustained and cross-variant SARS-CoV-2 neutralising antibodies (NAbs) in multiple animal models. Alhydroxiquim-II is a TLR7/8 small-molecule agonist chemisorbed on aluminium hydroxide. Vaccination with Alhydroxiquim-II combined with a stabilized, trimeric form of the SARS-CoV-2 spike protein (termed CoVac-II) resulted in high-titre NAbs in mice, with no decay in responses over an 8-month period. NAbs from sera of CoVac-II-immunized mice, horses and rabbits were broadly neutralising against SARS-CoV-2 variants. Boosting long-term CoVac-II-immunized mice with adjuvanted spike protein from the Beta variant markedly increased levels of NAb titres against multiple SARS-CoV-2 variants; notably high titres against the Delta variant were observed. These data strongly support the clinical assessment of Alhydroxiquim-II-adjuvanted spike proteins to protect against SARS-CoV-2 variants of concern. | en_AU |
dc.language.iso | en | en_AU |
dc.subject | COVID-19 | en_AU |
dc.subject | Coronavirus | en_AU |
dc.title | Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens | en_AU |
dc.type | Preprint | en_AU |
dc.subject.asrc | 11 Medical and Health Sciences | en_AU |
dc.subject.asrc | 1107 Immunology | en_AU |
dc.identifier.doi | 10.1101/2021.08.18.456891 | |
dc.relation.other | National Institute of Nursing Research; European Commission; Centers for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases | en_AU |
Associated file/s
There are no files associated with this item.
Associated collections